hit counter
Amneal Pharmaceuticals, Inc. (AMRX) Stock News Sentiment & Price - Sentifly
AMRX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Amneal Pharmaceuticals, Inc. (AMRX)

USA
Drugs - Generic
NYSE
AMRX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AMRX Latest news
Seeking Alpha
Neutral
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2021 Results - Earnings Call Transcript
2021-11-03 15:09

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2021 Results - Earnings Call Transcript

Benzinga
Positive
Amneal Posts Mixed Bag Q3 Earnings; Acquires Puniska To Bolster Injectable Business
2021-11-03 10:09

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q3 revenue of $529 million, a marginal increase of 2% Y/Y, missing the consensus of $545.06 million. The increase was driven by Generic product launches and growth in Specialty products Rytary and Unithroid, partially offset by price erosion in its base business and slow demand at the start of the flu season.

Zacks Investment Research
Positive
Amneal Pharmaceuticals (AMRX) Tops Q3 Earnings Estimates
2021-11-03 09:12

Amneal (AMRX) delivered earnings and revenue surprises of 5.00% and -3.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
Amneal Reports Third Quarter 2021 Financial Results
2021-11-03 06:00

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the third quarter ended September 30, 2021. “Our solid third quarter results further validate our strategy for growth and value creation, focused on operational excellence and a robust innovation engine to strengthen and diversify Amneal,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “We are pleased to be raising our adjusted EBITDA guidance for

Business Wire
Neutral
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
2021-11-02 08:00

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its inaugural Corporate Responsibility Report with primarily 2020 data and select 2021 highlights. This initial report provides stakeholders with details around the Company's commitment to good environmental, social and governance (ESG) practices that are strategic, impactful, and embedded into the Company's culture. The report highlights five key areas of imp

Zacks Investment Research
Positive
Amneal Pharmaceuticals (AMRX) to Report Q3 Results: Wall Street Expects Earnings Growth
2021-10-29 16:48

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire
Neutral
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
2021-10-27 08:00

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA). Dexamethasone, the generic version of Decadron®, is a well-established anti-inflammatory glucocorticoid steroid used to treat several medical conditions, including respiratory complications associated with COVID-19. “T

Zacks Investment Research
Positive
Why the Earnings Surprise Streak Could Continue for Amneal (AMRX)
2021-10-25 13:35

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Business Wire
Neutral
Amneal to Report Third Quarter 2021 Results on November 3, 2021
2021-10-06 08:00

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2021 financial results on Wednesday, November 3, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on November 3, 2021. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amn

Business Wire
Neutral
Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference
2021-09-07 08:00

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conference held on September 15, 2021. The presentation will begin at 1:15 PM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. A replay of the webcast will be posted shortly after the call and will be avail

Loading more news...